Aurelia Butler

The International Criminal Court (ICC) has issued arrest warrants for two Israeli officials, former Prime Minister Benjamin Netanyahu and Defense Minister Yoav Gallant, for alleged war crimes and crimes against humanity. The ICC’s Pre-Trial Chamber I announced the decision today, asserting jurisdiction over the State of Palestine and rejecting Israel’s challenges to the court’s authority.The ICC’s ruling addressed two separate challenges submitted by Israel on September 26, 2024. The first contested the court’s jurisdiction over Israeli nationals, while the second requested a halt to proceedings and a new notification of investigation initiation. The chamber dismissed both challenges, stating that the court could exercise jurisdiction based on the territorial jurisdiction of Palestine and that a new notification was unnecessary as Israel had been informed of the investigation in 2021.The warrants, which were initially kept secret to protect witnesses and the integrity of the investigation, were made public due to ongoing similar conduct and in the interest of victims and their families. The chamber found reasonable grounds to believe that Netanyahu and Gallant were responsible for the war crime of using starvation as a method of warfare and for crimes against humanity, including murder, persecution, and other inhumane acts against civilians in Gaza from at least October 8, 2023, to May 20, 2024.The chamber’s decision highlighted that the alleged crimes were part of a widespread and systematic attack against the civilian population of Gaza, noting that the restrictions on humanitarian aid and essential goods were often conditional and insufficient to meet the needs of the population. The ICC also found grounds to believe that Netanyahu and Gallant failed to prevent or repress the commission of crimes or ensure proper investigation into the matters.The warrants stem from a declaration by the State of Palestine accepting the ICC’s jurisdiction since June 13, 2014, and its accession to the Rome Statute in January 2015. The situation in the State of Palestine was referred to the ICC Prosecutor by Palestine in May 2018, with further referrals from several other countries in late 2023 and early 2024.The ICC’s decision marks a significant move in the ongoing legal proceedings surrounding the situation in Palestine.This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. More

Tom Barkin, president of the Richmond Fed and a voting member of the Federal Open Market Committee this year, told the Financial Times that while inflation is likely to continue declining, recent progress has slowed, as indicated by monthly government data.He expressed concern over businesses passing on costs to consumers more readily than in previous years, although not as aggressively as during the pandemic. This shift, Barkin noted, is contributing to persistent pricing pressures.“We’re somewhat more vulnerable to cost shocks on the inflation side, whether they be wage-[related] or otherwise, than we might have been five years ago,” he said.Barkin, who previously served as chief risk officer at McKinsey, highlighted businesses’ apprehensions about Trump’s proposed tariffs and immigration policies, which could have inflationary effects. “I can see why the businesses think that,” he said, while adding that Trump’s emphasis on boosting domestic energy production “might be disinflationary.”US economists share these concerns, cautioning that broad tariffs on imports could stoke inflation depending on their implementation. They also warn that mass deportations could drive up prices while hindering economic growth, potentially triggering stagflation. However, Trump and his advisers dispute these claims, arguing that deregulation and tax cuts will strengthen the economy without fueling inflation.Barkin emphasized that the Federal Reserve should not preemptively adjust its monetary policy in response to anticipated changes in government policy. “We shouldn’t try to solve it before it happens,” he said.The Fed has already reduced interest rates twice this year and is considering another cut at its December meeting. Fed Chair Jay Powell recently stated that the central bank is in no rush to push rates to levels that might curb growth, citing the economy’s resilience.While Barkin declined to speculate on the December meeting’s outcome, he stressed that future decisions will rely on incoming economic data. “If you’ve got inflation staying above our target, that makes the case to be careful about reducing rates,” he said. “If you’ve got unemployment accelerating, that makes the case to be more forward-leaning.”Describing the Fed’s recent actions as a “recalibration,” Barkin suggested that questions around the pace of rate adjustments would become more relevant as the Fed approaches a “normalization phase,” bringing monetary policy closer to a “neutral” stance. More

Incoming U.S. President Donald Trump promised to impose tariffs on most imports and said Europe would pay a big price for having run a huge trade surplus for years.”Trade tensions are rising,” Patsalides told a conference. “If trade restrictions materialise, the outcome may be inflationary, recessionary or worse, stagflationary,” Patsalides said.Still, the ECB could for now continue to lower interest rates with the next move possibly coming in December, Patsalides added.”While growth in the euro area economy has been anaemic for some time now, the approach to rate cuts must be gradual and data driven,” Patsalides said. “If incoming data and new projections in December confirm our baseline scenario, there would be room to continue lowering rates at a steady pace and magnitude.” The ECB has cut rates by a combined 75 basis points to 3.25% this year and investors have fully priced in another move on Dec 12, with most also expecting cuts at each policy meeting through next June. But Patsalides also warned that inflationary pressures, particularly from potential supply shocks, still pose a risk as does the sticky nature of services price growth.Inflation has fallen rapidly in recent months and was now expected to oscillate around the 2% target in the coming months. It could then settle at the target in the first half of the 2025, earlier than the ECB last predicted. More

(Reuters) – I have been enrolled in traditional Medicare for a couple of years now, and one professional benefit is that I receive the same direct marketing pitches that my readers get every year from health insurance companies during the annual fall enrollment season.Much of it encourages me to enroll in Medicare Advantage – the commercially offered managed-care alternative to the traditional program. And this year, Advantage plan marketers have a new enticement: the changes that take effect next year in Medicare’s Part D prescription drug coverage. If you are enrolled in traditional Medicare, this pitch should throw up a big red flag, because shifting to Advantage is something you might later regret – and it can be difficult to reverse. The Part D reforms are important, and generally positive. The big change for 2025 is a hard cap on out-of-pocket prescription costs. This reform was phased in under the Inflation Reduction Act of 2022 championed by the Biden administration and Democrats in Congress. Previously, there was no limit to what you might pay if you needed high-cost drugs for conditions like cancer and multiple sclerosis.This year, the cap is $3,300; the final step is a $2,000 cap in 2025. This will provide thousands of dollars in relief to seniors – about 4.6 million Medicare Part D enrollees had already reached $2,000 or more in out-of-pocket drug costs by the end of June this year, according to federal government data. It also will give seniors greater predictability in planning their healthcare spending.But health insurance companies are revising their offerings to a greater extent than usual for next year because of changes required by the Act. If you are enrolled in traditional Medicare with a standalone Part D plan, you may find your premium jumping, or changes in deductibles or cost-sharing arrangements. That means it is important to re-check your coverage this autumn if you are in a standalone plan. The same is true if you have a Medicare Advantage plan with drug coverage wrapped in with no extra premium – the terms of that drug coverage may be changing, too.Health insurance companies are using these changes to convince traditional Medicare enrollees to shift into Advantage. I received a letter recently from  my own current prescription drug plan provider, which I am dropping because the premium and projected total costs are jumping sharply. “Since your plan premiums are increasing in 2025, now is the time to explore your plan options,” the letter states. “(Our Medicare Advantage plan) may be a better fit for you. Plus, switching to (our Advantage plan) could lower what you pay for prescriptions and monthly premiums next year.” The letter goes on to pitch the usual Advantage enticements, such as dental coverage, gym membership and the like.This is a very compelling pitch – no wonder Medicare Advantage enrollment has been growing so quickly in recent years. More than half of eligible Medicare beneficiaries (54%) are enrolled in Medicare Advantage in 2024, a figure projected to hit 64% by 2034, according to KFF, a healthcare policy research organization. But here are a few things the letter does not say: – Instead of switching to Advantage, another option that I have is to simply search the Medicare Plan Finder for a less costly Part D plan. That is what I did – instead of a $35 increase, my premium actually will fall about $25 per month in 2025, as will total projected annual costs including the deductible and cost-sharing. – I might need to look for new doctors. If I join this Advantage plan, I will need to restrict myself to in-network healthcare providers in order to access the cost savings described in the letter, possibly causing disruption to my current healthcare.- I probably cannot go back later. Enrollees in traditional Medicare (such as myself) usually pair their Part A, B and D coverage with a Medigap supplemental policy. If I drop that now in order to join a Medicare Advantage plan, I may not be able to get a Medigap down the road if I decide to go back to traditional Medicare. Medigap insurance providers are required to sell me a policy when I first sign up for Medicare, but down the road they can use pre-existing conditions to turn me away, unless I live in one of four states that have some amount of protected access rights for this critical supplemental coverage (New York, Connecticut, Massachusetts and Maine).- The drug coverage might not fit my needs. The drug coverage wrapped into an Advantage plan may – or may not – be the best fit for me, depending on the medications I take. It is important to evaluate not only the healthcare provider network, but the drug coverage.- Here is the big thing the letter does not say. Medicare Advantage might work just fine for younger and healthier retirees. But the highest rates of dissatisfaction in Advantage are reported by the oldest and sickest enrollees in the program. Consumer advocates who work with Medicare enrollees often report that the highest rates of Advantage disenrollment are among the oldest and sickest patients, who encounter problems with denial of care or extra red tape in the form of requests for prior authorization. During annual enrollment, the ad blitz for Medicare Advantage is intense, and it lacks any context about what it can mean to give up your traditional Medicare coverage.Annual enrollment ends on Dec. 7. It is always a good idea to review your Part D or Advantage plan coverage, so start by consulting the federal government’s Medicare Plan Finder. If you need assistance help, consult your State Health Assistance Program. The opinions expressed here are those of the author, a columnist for Reuters. More